WO2003019142A3 - Compositions and methods for detection and regulation of genes associated with ruptured atherosclerotic plaque - Google Patents

Compositions and methods for detection and regulation of genes associated with ruptured atherosclerotic plaque Download PDF

Info

Publication number
WO2003019142A3
WO2003019142A3 PCT/US2002/026913 US0226913W WO03019142A3 WO 2003019142 A3 WO2003019142 A3 WO 2003019142A3 US 0226913 W US0226913 W US 0226913W WO 03019142 A3 WO03019142 A3 WO 03019142A3
Authority
WO
WIPO (PCT)
Prior art keywords
perilipin
hsl
adrp
lipid
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/026913
Other languages
French (fr)
Other versions
WO2003019142A9 (en
WO2003019142A2 (en
Inventor
Andrew S Greenberg
Mat J A P Daemen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Maastricht
Tufts University
Original Assignee
Universiteit Maastricht
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Maastricht, Tufts University filed Critical Universiteit Maastricht
Priority to AU2002324776A priority Critical patent/AU2002324776A1/en
Publication of WO2003019142A2 publication Critical patent/WO2003019142A2/en
Anticipated expiration legal-status Critical
Publication of WO2003019142A3 publication Critical patent/WO2003019142A3/en
Publication of WO2003019142A9 publication Critical patent/WO2003019142A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Compositions and methods for detecting tissue specificity for expression of perilipin, Hormone Sensitive Lipase (HSL) and Adipocyte Differentiation Related Protein (ADRP) mRNA and polypeptide are provided, and show that perilipin mRNA is located in plaques containing a thrombus, and perilipin polypeptide is found in foam cells of intimal xanthomas, in the shoulder area of stable lesions, and near the site of cap rupture in lesions containing a thrombus. HSL expression increases during plaque progression, and co-localizes to the same sites as perilipin. ADRP is expressed in all stages of human atherosclerosis, and is most important during the initial phases of lipid uptake. Perilipin expression increases in more lipid-laden macrophage derived foam cells, and replaces ADRP on the surface of the lipid droplet, thereby regulating accessibility to the lipolytic enzyme HSL. Perilipin and HSL are markers for progression of atherosclerosis associated with ruptured plaque.
PCT/US2002/026913 2001-08-23 2002-08-22 Compositions and methods for detection and regulation of genes associated with ruptured atherosclerotic plaque Ceased WO2003019142A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002324776A AU2002324776A1 (en) 2001-08-23 2002-08-22 Compositions and methods for detection and regulation of genes associated with ruptured atherosclerotic plaque

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31432901P 2001-08-23 2001-08-23
US60/314,329 2001-08-23

Publications (3)

Publication Number Publication Date
WO2003019142A2 WO2003019142A2 (en) 2003-03-06
WO2003019142A3 true WO2003019142A3 (en) 2004-04-15
WO2003019142A9 WO2003019142A9 (en) 2004-05-27

Family

ID=23219531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/026913 Ceased WO2003019142A2 (en) 2001-08-23 2002-08-22 Compositions and methods for detection and regulation of genes associated with ruptured atherosclerotic plaque

Country Status (2)

Country Link
AU (1) AU2002324776A1 (en)
WO (1) WO2003019142A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007128796A1 (en) * 2006-05-05 2007-11-15 Universiteit Maastricht / Carim Peptides for use in diagnosing the presence of ruptured atherosclerotic lesions in an individual
EP2839292A4 (en) * 2012-04-19 2015-08-26 Univ California COMPOSITIONS AND METHODS FOR DETECTING INSTABLE ATHEROSCLEROSIS PLATES
EP3695883A1 (en) * 2019-02-13 2020-08-19 Alytas Therapeutics GmbH Means for specifically eliminating perilipin-1 fragment presenting adipocytes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585462A (en) * 1991-06-11 1996-12-17 United States Of America Cloning of perilipin proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585462A (en) * 1991-06-11 1996-12-17 United States Of America Cloning of perilipin proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLANCHETTE-MACKIE ET AL.: "Perilipin is located on the surface layer of intracellular lipid droplets in adipocytes", J. LIPID RES., vol. 36, no. 6, June 1995 (1995-06-01), pages 1211 - 1226, XP002973237 *
FABER ET AL.: "Identification of genes potentially involved in rupture of human atherosclerotic plaques", CIRC. RES., vol. 89, no. 6, 14 September 2001 (2001-09-14), pages 547 - 554, XP002244261 *
GREENBERG ET AL.: "Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein associted with the periphery of lipid storage droplets", J. BIOL. CHEM., vol. 266, no. 17, 15 June 1991 (1991-06-15), pages 11341 - 11346, XP002973236 *
MEIJER J.D., March 1998, THESIS WRITEN AT THE BIOCHEMICAL PHYSIOLOGY RESEARCH GROUP, DEPARTMENT OF EXPERIMENTAL ZOOLOGY, UNIVERSITY AT UTRECHT, article "Hormone sensitive lipase: structure, function and regulation", pages: 6 - 38, XP002973238 *
SCHWARTZ ET AL.: "Molecular markers, fibrous cap rupture and the vulnerable plaque: New experimental opportunities", CIRC. RES., vol. 89, no. 6, 14 September 2001 (2001-09-14), pages 471 - 473, XP002973239 *

Also Published As

Publication number Publication date
AU2002324776A1 (en) 2003-03-10
WO2003019142A9 (en) 2004-05-27
WO2003019142A2 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
Fan et al. Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor-α converting enzyme and of an alternatively translated polypeptide
Bae et al. Concerted action of sulfiredoxin and peroxiredoxin I protects against alcohol‐induced oxidative injury in mouse liver
Chauhan et al. Purification and characterization of human serum biotinidase.
Caughey Roles of mast cell tryptase and chymase in airway function
Margatan et al. Angiotensin converting enzyme inhibitory activity of soy protein subjected to selective hydrolysis and thermal processing
AU2001249874A1 (en) System and method for assessing transmurality of ablation lesions
AU1093001A (en) Method for determining lipid and protein content of tissue
WO1999031227A3 (en) NOVEL PEPTIDE, apoEp1.B, COMPOSITIONS AND USES THEREOF
AU2010241524A1 (en) Variant lipolytic enzymes
WO2003006652A3 (en) Inhibition of specific histone deacetylase isoforms
KR20070077515A (en) Promote the activity of lysyl oxidase isoenzymes to control diseases caused by incomplete, lack or dissolution of elastic fiber formation
WO2001000220A3 (en) Lipoprotein lipase (lpl) variant therapeutics
Burnette et al. Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir
Chestukhin et al. Unveiling the substrate specificity of meprin β on the basis of the site in protein kinase A cleaved by the kinase splitting membranal proteinase
AU5911100A (en) Genetic test to determine non-responsiveness to statin drug treatment
EP1576095A3 (en) Fatty alcohol oxidase genes and proteins from candida troplicalis and methods relating thereto
WRAIGHT et al. Comparison of ornithine transcarbamylase from rat liver and intestine: evidence for differential regulation of enzyme levels
Wilk et al. Identification of histidine residues important in the catalysis and structure of aspartyl aminopeptidase
Jayne et al. High expression in adult horse of PLRP2 displaying a low phospholipase activity
AU2002221755A1 (en) Nucleotide and polypeptide sequence of human lysosomal acid lipase
Schmaler et al. Control of Deneddylation by the COP9 Signalosome
EP2934474A1 (en) Modulation of melanogenesis by modification of tyrosinase by palmitoylation
WO1999051756A3 (en) Promoter and constructions for expression of recombinant proteins in filamentous fungi
WO2001049831A3 (en) Xylosyltransferase and isoforms thereof
Hanson et al. Hydrolysis of big endothelin-1 by a serine protease in the membrane fraction of human lung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP